The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zongertinib in HER2-altered breast cancer: Preclinical activity and preliminary results from a phase Ia dose-escalation study.
 
David Berz
Employment - Valkyrie Clinical Trials
Leadership - Jazz Pharmaceuticals; Sun Pharma
Honoraria - EMD Serono; Jazz Pharmaceuticals; Sun Pharma
Research Funding - Ascendis Pharma; BeiGene; BioNTech; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb; eFFECTOR Therapeutics; Faeth Therapeutics; G1 Therapeutics; Genprex; Hongyun Biotech; Incyte; InhibRx; Mirati Therapeutics; Seagen; Summit Therapeutics; WhiteOak; Xencor
Travel, Accommodations, Expenses - EMD Serono; Jazz Pharmaceuticals
 
Frans Opdam
Consulting or Advisory Role - iomx (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca/Merck (Inst); Boehringer Ingelheim (Inst); Cytovation (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Kinnate Biopharma (Inst); Merus NV (Inst); Pierre Fabre (Inst); Relay Therapeutics (Inst); Taiho Oncology (Inst)
 
Daniela Maier
Employment - Boehringer Ingelheim
 
Kerstin Moeldner
Employment - Boehringer Ingelheim
 
Martin Augsten
Employment - Boehringer Ingelheim
 
Anke Baum
Employment - Boehringer Ingelheim
 
Irene Waizenegger
Employment - Boehringer Ingelheim
 
Behbood Sadrolhefazi
Employment - Boehringer Ingelheim
 
John Heymach
Employment - MD Anderson Cancer Center
Consulting or Advisory Role - AstraZeneca; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; DAVA Pharmaceuticals; EMD Serono; Genentech/Roche; GlaxoSmithKline; Hengrui Pharmaceutical; Janssen; Jazz Pharmaceuticals; Jazz Pharmaceuticals; Lilly (Inst); Mirati Therapeutics; Nexus Health Systems; Pneuma Respiratory; Regeneron; Sanofi/Aventis; Spectrum Pharmaceuticals; Takeda
Speakers' Bureau - DAVA Pharmaceuticals; IDEOlogy Health; MJH Life Sciences
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics; Spectrum Pharmaceuticals; Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations; Patents pending regarding subtyping of SCLC lung cancer.
 
Noboru Yamamoto
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; CMIC; Eisai; Healios; Merck; Mitsubishi Tanabe; Noile-Immune Biotech, Inc; Rakuten Medical Japan
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Carna Biosciences (Inst); Chiome Bioscience (I); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genmab/Seattle Genetics (Inst); GlaxoSmithKline (Inst); InventisBio (Inst); Janssen (Inst); Kaken Pharmaceutical (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (I); Pfizer (Inst); Rakuten Medical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toray Industries (Inst)
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research